Acumen Pharmaceuticals (ABOS) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 3, 2026, to be held virtually, with voting on three main proposals: election of directors, ratification of the auditor, and approval of an amended equity incentive plan.

• Stockholders of record as of April 8, 2026, are eligible to vote, with 72,227,580 shares outstanding.

• Proxy materials are provided online to reduce costs and environmental impact, with options for mail delivery upon request.

Voting matters and shareholder proposals

• Proposal 1: Elect three Class II directors (George Golumbeski, Derrell Porter, Laura Stoppel) for terms expiring in 2029.

• Proposal 2: Ratify Ernst & Young LLP as independent auditor for fiscal year 2026.

• Proposal 3: Approve the Amended and Restated 2021 Equity Incentive Plan, increasing shares by 10 million, removing the evergreen provision, and prohibiting repricing without shareholder approval.

• Board recommends voting FOR all proposals.

• Shareholder proposals for the 2027 meeting must be submitted by December 24, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• Board consists of eight members, with a majority deemed independent under Nasdaq standards.

• Board leadership is separated, with an independent chair (Dr. Golumbeski).

• Three standing committees: Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.

• Board and committee meetings had high attendance, and all directors attended the prior annual meeting.

• Stockholders can communicate directly with the Board, and a code of ethics and corporate governance guidelines are in place.